Calgary, Alberta and Isle of Man (Newsfile Corp. - February 18, 2021) - Real Luck Group Ltd. (TSXV: LUCK) (the "Company") and its subsidiary companies doing business as "Luckbox" (the "Group"), a provider
Pan American Silver reports record operating cash flow of $462 3 million in 2020 investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Appia Energy Corp.: Appia Confirms Monazite as the Source for High-Grade Gallium, Alces Lake Property
Toronto, Ontario (Newsfile Corp. - February 17, 2021) -
Appia Energy Corp. (CSE: API) (OTCQB: APAAF) (FSE: A0I.F) (FSE: A0I.MU) (FSE: A0I.BE) (the Company or Appia ) is pleased to announce the confirmation that monazite is the mineral host for high-grade gallium consistently observed in lithogeochemical assay results on the Company s Alces Lake high-grade rare earth element (
REE ), gallium and uranium property (the
Property ), northern Saskatchewan.
Study ) was conducted by the Saskatchewan Research Council (
SRC ) on two samples previously submitted to SRC for lithogeochemical assay testing. The Study successfully showed that monazite from two separate REE zones and trends, Ivan and WRCB, contain similar concentrations of gallium oxide (Ga
Terra Nova Resources Inc. is pleased to announce the appointment of a Program Development Manager within WellteQ, the acquisition target seeking imminent CSE listing by way of Reverse Takeover.
Terra Nova Resources Inc. (CSE: TENO) (the “Company” or “Terra Nova”) is pleased to announce the appointment of a Program Development Manager within WellteQ, the acquisition target seeking imminent CSE listing by way of Reverse Takeover (RTO).
WellteQ, one of Asia Pacific’s most advanced digital health companies, is proud to announce the appointment of Ms Gretchen Masters as Program Development Manager. Ms Masters has recently departed nib, Australia’s third largest health insurer where she ran a team responsible for the development and delivery of Well with nib, a digital solution that is designed to motivate nib’s two million members to engage in healthier habits and decrease health risk.
for Uterine Fibroids
ObsEva is developing Yselty®, an oral GnRH receptor antagonist with the potential to treat more women thanks to its potential best-in-class efficacy, a favorable tolerability profile and unique, flexible dosing options for the treatment of uterine fibroids. Following the European Medicine Agency’s (EMA) recent validation of the marketing authorization application (MAA), a major milestone toward making Yselty® available in the E.U., the Company will continue to work closely with the EMA to achieve marketing approval, projected in Q4:2021.
The second key objective for 2021 will be to submit a U.S. New Drug Application (NDA), projected in Q2:2021, that will include the Week 76 post-treatment follow-up results from the Phase 3 PRIMROSE 1 (US only; n=574) and PRIMROSE 2 (Europe and US; n=535) clinical studies. In both studies, patients with heavy menstrual bleeding (HMB) associated with uterine fibroids were administered Yselty doses of 100 mg or 200 mg, with a